Viewing Study NCT04923893


Ignite Creation Date: 2025-12-25 @ 1:26 AM
Ignite Modification Date: 2025-12-27 @ 11:13 PM
Study NCT ID: NCT04923893
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-05
First Post: 2021-06-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Sponsor: Janssen Research & Development, LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module